Dyspepsia laboratory findings
|
Dyspepsia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dyspepsia laboratory findings On the Web |
|
American Roentgen Ray Society Images of Dyspepsia laboratory findings |
|
Risk calculators and risk factors for Dyspepsia laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2]
Overview
There is no diagnostic laboratory test for dyspepsia itself. Laboratory evaluation serves three purposes: to detect anemia or other findings that redirect the diagnosis away from functional dyspepsia (FD), to establish Helicobacter pylori status for a test-and-treat strategy and to confirm eradication, and, in selected patients, to investigate uncommon organic causes such as Zollinger-Ellison syndrome (ZES).[1][2] Current guidance favors a targeted approach; reflexive laboratory panels are low-yield, costly, and may reinforce illness behavior.[1][2]
Laboratory Findings
Initial Laboratory Testing
A complete blood count (CBC) is the one test with broad support at initial evaluation. Its value lies in detecting iron deficiency anemia, an alarm feature that mandates endoscopy and removes the patient from the FD pathway; no CBC pattern is specific for dyspepsia.[3][1] All other testing is symptom-directed. The 2026 Rome gastroduodenal disorders update states that routine laboratory testing, including celiac serology, is not supported by international consensus, whereas H. pylori status should be determined in every patient with dyspeptic symptoms.[2]
| Test | Indication | Comment |
|---|---|---|
| CBC | Initial evaluation | Iron deficiency anemia is an alarm feature requiring endoscopy[3][1] |
| H. pylori testing | All patients with dyspeptic symptoms | Use an active-infection test (see below)[2] |
| Liver chemistries | Suspected hepatobiliary source (e.g., severe episodic epigastric or right upper quadrant pain) | Not routine[3][4] |
| Lipase / amylase | Clinically suspected pancreatitis | Routine screening explicitly not recommended[3] |
| Celiac serology | Features raising pretest probability (e.g., overlapping IBS-type symptoms) | Low yield when ordered routinely[2][5] |
| Thyroid function | Not indicated routinely | —[3] |
Helicobacter pylori Testing
H. pylori testing is the central laboratory step in uninvestigated dyspepsia. Test-and-treat is endorsed for patients <60 years without alarm features (vomiting, gastrointestinal bleeding, unexplained iron deficiency, weight loss) and without other indications for endoscopy; a lower threshold of approximately 50 years applies in populations at higher gastric cancer risk.[6]
Choice of Test
| Test | Detects | Diagnostic performance | Initial diagnosis | Test of cure |
|---|---|---|---|---|
| Urea breath test (UBT; 13C or 14C) | Active infection | Sensitivity and specificity typically >95%[7][8]; outperforms serology and stool antigen on network meta-analysis[9] | Preferred | Preferred |
| Stool antigen test (SAT; monoclonal) | Active infection | Sensitivity and specificity >90–97%[10][7] | Preferred; lower cost than UBT | Preferred; accuracy comparable to UBT |
| Serology (IgG) | Prior exposure; cannot distinguish active from past infection | — | Not recommended to confirm active infection; if used, limit to treatment-naïve patients in high-prevalence settings[7][8] | Not recommended; antibodies persist for months to years |
Pre-test Medication Washout
Acid suppression and antimicrobials reduce bacterial load and cause false-negative UBT and SAT results:
- Proton pump inhibitors (PPIs): withhold for 2 weeks before testing[6]; some U.S. sources advise up to 30 days.[8]
- Bismuth and antibiotics: withhold for ≥4 weeks.[6]
- Standard-dose H2 receptor antagonists and antacids: need not be stopped and can control symptoms during the washout period.[6][8]
- Potassium-competitive acid blockers (e.g., vonoprazan): effect on test accuracy is not well studied; similar precautions likely apply.[6]
Confirmation of Eradication (Test of Cure)
Because U.S. eradication rates have declined, test of cure is recommended in all treated patients regardless of symptoms; symptom response correlates poorly with microbiologic cure.[6]
- Use UBT or monoclonal SAT performed ≥4 weeks after completing therapy, with PPIs held for 2 weeks and bismuth/antibiotics held for 4 weeks beforehand.[6]
- Do not use serology; antibodies persist for months to years after cure.[8]
- Rapid urease testing is not recommended to confirm eradication.[11]
Serum Gastrin and Evaluation for Zollinger-Ellison Syndrome
Serum gastrin is not part of routine dyspepsia evaluation. It is reserved for red-flag ulcer phenotypes: peptic ulcers not attributable to NSAIDs or H. pylori, recurrent, refractory, or multiple ulcers, ulcers with chronic diarrhea, and ulcers with MEN1 or hypercalcemia.[12][13]
- Fasting serum gastrin is the initial test and is elevated in 97–99% of patients with ZES. Ideally draw it off PPI for ≥1 week (H2 receptor antagonist for 48 hours), since PPI-induced hypochlorhydria is a common cause of hypergastrinemia.[14][15]
- Caution: PPI withdrawal in true ZES risks acid rebound and ulcer complications. In patients with active symptoms, hold PPIs only under specialist guidance or bridge with an H2 receptor antagonist.[16][17]
- Exclude common causes of hypergastrinemia first: atrophic gastritis, H. pylori pangastritis, renal failure, and PPI use.[12]
| Finding | Interpretation | Next step |
|---|---|---|
| Fasting gastrin >10× ULN (>1000 pg/mL) with gastric pH <2 | Diagnostic of ZES | Tumor localization and staging[12][14] |
| Intermediate gastrin elevation (<10× ULN) with gastric pH <2 | Nondiagnostic | Secretin stimulation test: rise of >120 pg/mL above baseline has ~94% sensitivity and ~100% specificity[12][14] |
| Elevated gastrin without gastric pH <2 | Secondary hypergastrinemia more likely | Evaluate for PPI use, atrophic gastritis, H. pylori pangastritis, renal failure[12] |
Areas of Uncertainty
| Issue | Current positions |
|---|---|
| PPI washout before UBT/SAT | 2 weeks (ACG, Maastricht)[6] vs up to 30 days (some U.S. recommendations)[8] |
| UBT vs SAT | ACG does not favor either and notes the lower cost of SAT; Maastricht has historically favored UBT for slightly higher accuracy[8][9] |
| Role of serology | Contraindicated in some national guidelines; conditionally allowed for cost reasons in others[11] |
| Potassium-competitive acid blockers | Effect on UBT/SAT accuracy unresolved[6] |
| Biomarker-based FD stratification | Investigational; not part of routine evaluation[5] |
Common Pitfalls
| Pitfall | Consequence | Correct practice |
|---|---|---|
| H. pylori testing or test of cure while on a PPI | False-negative result | Hold PPI 2 weeks and antibiotics/bismuth 4 weeks; use H2 receptor antagonists or antacids for symptoms[6] |
| Serology used to confirm eradication | False-positive result from persistent antibodies | Use UBT or monoclonal SAT ≥4 weeks after therapy[8] |
| Reflex panels (lipase/amylase, thyroid, celiac serology) without indication | Low yield, cost, reinforcement of illness behavior | Symptom-directed testing only[3][2] |
| Overlooking iron deficiency anemia on CBC | Missed organic disease under an FD label | Treat iron deficiency anemia as an alarm feature requiring endoscopy[3] |
| Drawing gastrin on a PPI | Drug-induced hypergastrinemia misread as ZES | Draw off PPI when safe; interpret with gastric pH[14] |
| Abrupt PPI withdrawal in suspected ZES | Acid rebound and ulcer complications | Specialist-guided withdrawal or H2 receptor antagonist bridge[16] |
| Applying the older 55-year age threshold | Outdated test-and-treat eligibility | Use <60 years (≈50 years in high gastric-cancer-risk populations)[6] |
References
- ↑ 1.0 1.1 1.2 1.3 Sayuk GS, Gyawali CP (2020). "Functional dyspepsia: diagnostic and therapeutic approaches". Drugs.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Törnblom H, et al. Rome gastroduodenal disorders update. Gastroenterology. 2026.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Ford AC; et al. (2020). "Functional dyspepsia". Lancet.
- ↑ Lacy BE, Cash BD. JAMA. 2008.
- ↑ 5.0 5.1 Camilleri M, BouSaba J. Clin Gastroenterol Hepatol. 2023.
- ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 Chey WD; et al. (2024). "ACG Clinical Guideline: Treatment of Helicobacter pylori Infection". Am J Gastroenterol.
- ↑ 7.0 7.1 7.2 Infectious Diseases Society of America (IDSA) and American Society for Microbiology (ASM). Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2024 update. 2024.
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 Crowe SE (2019). "Helicobacter pylori infection". N Engl J Med.
- ↑ 9.0 9.1 Best LM; et al. (2018). "Non-invasive diagnostic tests for Helicobacter pylori infection". Cochrane Database Syst Rev.
- ↑ Vakil N. JAMA. 2024.
- ↑ 11.0 11.1 Sun Y, et al. Systematic review of guidelines for Helicobacter pylori diagnosis. Syst Rev. 2025.
- ↑ 12.0 12.1 12.2 12.3 12.4 Chatzipanagiotou O, et al. J Neuroendocrinol. 2023.
- ↑ Mendelson AH, Donowitz M (2017). "Catching the zebra: clinical pearls and pitfalls for the successful diagnosis of Zollinger-Ellison syndrome". Dig Dis Sci.
- ↑ 14.0 14.1 14.2 14.3 Metz DC, Jensen RT (2008). "Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors". Gastroenterology.
- ↑ Rossi RE, et al. World J Gastroenterol. 2021.
- ↑ 16.0 16.1 Hofland J, et al. Nat Rev Endocrinol. 2018.
- ↑ National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. 2026.